In the second largest M&A deal of 2019 so far, AbbVie has agreed to acquire Allergan for approximately US$63 B in an effort to ease investor concerns regarding AbbVie’s over-reliance on Humira® (adalimumab). With the deal, AbbVie gains Allergan’s medical aesthetics portfolio, which garnered sales of US$4.3 B in 2018, as well as enhanced portfolio in immunology, neuroscience, women’s health and eye care.